Update on Biologics for Psoriasis in Clinical Practice

Ivanic, Mirjana G

doi:10.12788/cutis.0317

Cited by 7 publications

(7 citation statements)

References 8 publications

(15 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[32][33][34][35] Derzeit zugelassene Biologika sind Etanercept, Infliximab, Adalimumab, Certolizumab Pegol sowie Golimumab (letzteres nur für Psoriasis-Arthritis [PsA]) gegen TNF-α, Secukinumab und Ixekizumab gegen IL-17A, Bimekizumab gegen IL-17A und IL-17F, Brodalumab gegen den IL-17-Rezeptor a/c, Ustekinumab gegen IL-12 und IL-23 sowie Guselkumab, Tildrakizumab und Risankizumab gegen IL-23. [36][37][38][39] Zu den jüngsten Entwicklungen gehören auch Mirikizumab (Entwicklung gegen Psoriasis eingestellt), Sonelokimab und Netakimab. 40,41 Diese spezifischen Therapeutika belegen eindrucksvoll, wie immunologische Grundlagenforschung und translationale Forschung zu hochwirksamen Medikamenten geführt haben, mit denen die meisten Patienten mit zumindest mittelschwerer Psoriasis gut und sicher behandelt werden können (Tabelle 1).…”

Section: Wo Stehen Wir?unclassified

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Schön

Wilsmann‐Theis

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDie Erforschung kaum einer anderen Erkrankung hat so grundlegend neue Erkenntnisse über immunologischen Regulationen und gleichzeitig eine derart rasante Entwicklung innovativer Therapien hervorgebracht wie das Studium der Psoriasis. In dieser kurzen Übersichtsarbeit umreißen wir die Grundzüge der aktuellen Psoriasisforschung unter besonderer Berücksichtigung pathophysiologischer Vorgänge und der Meilensteine bei der Zulassung verschiedener Biologika und niedermolekularer Pharmaka. Nicht zuletzt durch die Psoriasisforschung verstehen wir das Zusammenspiel der Komponenten des angeborenen und des adaptiven Immunsystems immer besser. Neue Therapeutika greifen dabei an entscheidenden Punkten in regulatorische Netzwerke ein. Ausgehend vom derzeitigen Kenntnisstand skizzieren wir einige aus unserer Sicht wesentliche zukünftige Forschungsrichtungen sowie therapeutische und klinische Entwicklungen im Bereich der Psoriasis. Diese reichen von der Erforschung genetischer, epigenetischer, zellulärer und immunologischer Mechanismen über die Untersuchung spezifischer klinischer Formen der Psoriasis und individueller systemischer Auswirkungen der Krankheit sowie ihrer Behandlung bis hin zur Einbeziehung von Big Data und künstlicher Intelligenz. Ziele sind ein ganzheitliches Verständnis der Psoriasis von der molekularen bis zur organismischen und gesellschaftlichen Ebene und darauf aufbauend individualisierte Präventions‐ und Behandlungsstrategien. Trotz beeindruckender Fortschritte muss die Psoriasisforschung sowohl im kleinen als auch im großen Maßstab weiterentwickelt werden, um den Bedürfnissen von Behandlern und Patienten noch besser gerecht zu werden.

show abstract

Section: Wo Stehen Wir?unclassified

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Schön

Wilsmann‐Theis

2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…6,7 Monoclonal antibodies targeting IL-17RA, such as brodalumab, or IL-17A, such as secukinumab and ixekizumab, have been approved for the treatment of psoriasis, indicating that the blockage of IL-17A/IL-17RA binding is a potent target for anti-psoriasis drugs. 8,9 Therefore, a platform for the analysis of natural compounds that targeted IL-17A and IL-17RA interaction was established in this study. Phenylpropanoids, such flavonoids and phenolic acids, are a large class of secondary metabolites derived from phenylalanine in most plants.…”

Section: Papermentioning

confidence: 99%

“…6,7 Because the hyper-proliferation of epidermal keratinocytes induced by IL-17A is the major pathogenesis of psoriasis, monoclonal antibody secukinumab that blocks the IL-17A/ IL-17A receptor (IL-17RA) interaction has been approved for the treatment of psoriasis. 8,9 However, the high price of secukinumab causes a heavy economic burden on patients with psoriasis.…”

Section: Introductionmentioning

confidence: 99%

Rosmarinic acid ameliorated psoriatic skin inflammation in mice through the novel inhibition of the interleukin-17A/interleukin-17A receptor interaction

Liu

et al. 2022

Food Funct.

View full text Add to dashboard Cite

show abstract

“… 3 , 4 , 5 , 6 The primary treatment options include topic agents, phototherapy, systematic immunosuppressants, and biologics (such as tumor necrosis factor alpha (TNF‐α) inhibitors, interleukin (IL)‐12/23 inhibitors, and IL‐17 inhibitors). 7 , 8 , 9 , 10 Among the biologics, etanercept is one of the most frequently administered TNF‐α inhibitors in China, which is effective in alleviating disease activity in psoriasis patients. 11 However, etanercept is expensive compared to conventional treatments, meanwhile, a number of psoriasis patients fail to response to etanercept or discontinue treatment due to side effects over time.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‐146a and microRNA‐146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients

Shen

Wang

Zhan

et al. 2021

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Background MicroRNA (miR)‐146a and miR‐146b regulate autoimmunity, inflammation, and keratinocytes proliferation to engage in psoriasis pathology. The current study aimed to investigate their correlation with disease risk and clinical features, and the linkage of their longitudinal changes with clinical response to etanercept in psoriasis patients. Methods Plasma samples were collected from 84 moderate‐to‐severe psoriasis patients who underwent etanercept treatment (at baseline (M0), 1 month (M1), 3 months (M3), and 6 months (M6)), 80 disease controls and 80 health controls (both after enrollment); afterward, miR‐146a and miR‐146b expressions were detected by RT‐qPCR. Furthermore, PASI75 and PASI90 responses were assessed in psoriasis patients. Results Both miR‐146a and miR‐146b were decreased in psoriasis patients compared with disease controls and health controls (all p < 0.001), which also distinguished psoriasis patients from disease controls and health controls by receiver‐operating characteristic analyses. Furthermore, miR‐146a positively correlated with miR‐146b in psoriasis patients (p < 0.001) and disease controls (p = 0.005) but not in healthy controls (p = 0.062). In psoriasis patients, miR‐146a negatively related to psoriatic body surface area (p = 0.011) and PASI score (p = 0.003); miR‐146b negatively linked with PASI score (p = 0.020). At M1, M3, and M6 after etanercept treatment, PASI75 response rate was 14.3%, 32.1%, and 69.0%, respectively; PASI90 response rate was 1.2%, 17.9%, and 36.9%, respectively. During etanercept treatment, both miR‐146a and miR‐146b elevated gradually over time and their longitude increments were associated with PASI75 response (all p < 0.001). Conclusion MiR‐146a and miR‐146b might serve as indicators for optimizing etanercept application and improving treatment outcomes in psoriasis patients.

show abstract

Update on Biologics for Psoriasis in Clinical Practice

Cited by 7 publications

References 8 publications

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Aktuelle Entwicklungen und Perspektiven bei Psoriasis

Rosmarinic acid ameliorated psoriatic skin inflammation in mice through the novel inhibition of the interleukin-17A/interleukin-17A receptor interaction

MicroRNA‐146a and microRNA‐146b deficiency correlates with exacerbated disease activity, and their longitude increment relates to etanercept response in psoriasis patients

Contact Info

Product

Resources

About